Currently, there are 43.67M common shares owned by the public and among those 32.89M shares have been available to trade.
Insiders at the company have transacted a total of 8 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 8 of these insider trades were purchases, accounting for 265,130 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 16.52, up 1.81%. The company’s stock has a 5-day price change of 24.26% and 210.29% over the past three months. YMAB shares are trading 138.86% year to date (YTD), with the 12-month market performance up to 278.84% higher. It has a 12-month low price of $2.70 and touched a high of $16.36 over the same period. YMAB has an average intraday trading volume of 342.35K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 29.36%, 73.68%, and 128.96% respectively.
Institutional ownership of Y-Mabs Therapeutics Inc (NASDAQ: YMAB) shares accounts for 49.90% of the company’s 43.67M shares outstanding.
It has a market capitalization of $710.57M and a beta (3y monthly) value of 0.72. The earnings-per-share (ttm) stands at -$0.44. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.73% over the week and 8.95% over the month.
Analysts forecast that Y-Mabs Therapeutics Inc (YMAB) will achieve an EPS of -$0.2 for the current quarter, -$0.2 for the next quarter and -$0.78 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.24 while analysts give the company a high EPS estimate of -$0.16. Comparatively, EPS for the current quarter was $0.03 a year ago. Earnings per share for the fiscal year are expected to increase by 69.36%, and -16.46% over the next financial year.
Looking at the support for the YMAB, a number of firms have released research notes about the stock. Wedbush stated their Outperform rating for the stock in a research note on May 10, 2023, with the firm’s price target at $5-$13.
